Rosellini is an interesting company and I had never heard of them before but there’s a lot going on out there today. This is a quote from their “about” page:
“At Rosellini Scientific, we empower freedom from disease by developing intelligent medical rehabilitation devices to support patients post-procedure. Our goal is to provide a suite of medical devices designed to support patients by preventing disease, restoring function, and enhancing quality of life. Our focus begins with patient rehabilitation in their hospital bed and continues to support daily life outside of the hospital environment. To facilitate patient rehabilitation, we distribute the most advanced technological healthcare solutions on the market. Where no therapy currently exists, we are actively developing solutions utilizing the interconnection of software, hardware, and biomedical implants. “
It continues on to say they finance medical records, purchase inventions and partner with strategic device manufacturing companies and thus so it appears that some Medtronic patents came into play here with some of what they are developing. It seems of late there’s been a lot in the news with companies “settling” patent issues and not just in healthcare as we had the big news about Twitter buying 900 patents from IBM as well. BD
Rosellini Scientific, Inc. announced today that it has acquired a medical device portfolio from Medtronic consisting of six U.S. and eight International patents. The patents, which relate to remote monitoring of implantable medical devices, will be developed in companies spun-out of Rosellini Scientific, all of whom will have a focus on enhancing the delivery of digital medicine at the point of care. This includes combinations of remote monitoring and treatment, hospital inventory management and electronic medical record integration.
The Company has recently formed CardiaX, Inc. to develop the CardioPT™ device, which will serve as a comprehensive solution for patients with advanced heart failure, atrial fibrillation, and ventricular arrhythmias leading to sudden cardiac death. The technology has received nearly $2 million in development funding.